Tripeptides from Allium Subhirsitum L. Extracts: Pharmacokinetics Properties, Toxicity Prediction and in Silico Study Against SARS-CoV-2 Enzymes and Pro-inflammatory Proteins
Overview
Authors
Affiliations
Developing new prophylactic and therapeutic agents with broad-spectrum antiviral activities is urgently needed to combat emerging human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since no available clinically antiviral drugs have been approved to eradicate COVID-19 as of the writing of this report, this study aimed to investigate bioactive short peptides from Allium subhirsutum L. (Hairy garlic) extracts identified through HR-LC/MS analysis that could potentially hinder the multiplication cycle of SARS-CoV-2 via molecular docking study. The obtained promising results showed that the peptides (Asn-Asn-Asn) possess the highest binding affinities of -8.4 kcal/mol against S protein, (His-Phe-Gln) of -9.8 kcal/mol and (Gln-His-Phe) of -9.7 kcal/mol towards hACE2, (Thr-Leu-Trp) of -10.3 kcal/mol and (Gln-Phe-Tyr) of -9.8 kcal/mol against furin. Additionally, the identified peptides show strong interactions with the targeted and pro-inflammatory ranging from -8.1 to -10.5 kcal/mol for NF-κB-inducing kinase (NIK), from -8.2 to -10 kcal/mol for phospholipase A2 (PLA2), from -8.0 to -10.7 kcal/mol for interleukin-1 receptor-associated kinase 4 (IRAK-4), and from -8.6 to -11.6 kcal/mol for the cyclooxygenase 2 (COX2) with Gln-Phe-Tyr model seems to be the most prominent. Results from pharmacophore, drug-likeness and ADMET prediction analyses clearly evidenced the usability of the peptides to be developed as an effective drug, beneficial for COVID-19 treatment.
Hatem B, Jabir F Biochem Genet. 2024; .
PMID: 39085685 DOI: 10.1007/s10528-024-10890-7.
Tiwari P, Chouhan M, Mishra R, Gupta S, Chaudhary A, Al-Zharani M Front Cell Infect Microbiol. 2024; 14:1391288.
PMID: 38919703 PMC: 11196402. DOI: 10.3389/fcimb.2024.1391288.
Van Giang T, Hoa L, Hien T, Cuong Q, Cap N, Vuong N Cureus. 2023; 15(7):e42484.
PMID: 37637574 PMC: 10452047. DOI: 10.7759/cureus.42484.
Hamadou W, Bouali N, Badraoui R, Hadj Lajimi R, Hamdi A, Alreshidi M Evid Based Complement Alternat Med. 2022; 2022:1518511.
PMID: 35966725 PMC: 9371847. DOI: 10.1155/2022/1518511.